B of A Securities Downgrades Conmed to Underperform, Maintains Price Target to $40
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsDowngradesPrice Target
B of A Securities analyst Travis Steed downgrades Conmed (NYSE:CNMD) from Neutral to Underperform and maintains the price target from $40 to $40.
B of A Securities analyst Travis Steed downgrades Conmed (NYSE:CNMD) from Neutral to Underperform and maintains the price target from $40 to $40.